Baseline characteristics
| . | DP-matched/ younger donor . | DP-matched/ older donor . | Permissive-mismatched/ younger donor . | Permissive- mismatched/ older donor . | Nonpermissive-mismatched/ younger donor . | Nonpermissive-mismatched/ older donor . |
|---|---|---|---|---|---|---|
| n = 1591 . | n = 526 . | n = 3845 . | n = 1184 . | n = 2659 . | n = 978 . | |
| Donor age; median, y (IQR) | 25.3 (22.4-28.9) | 41.7 (38.1-47) | 25.4 (22.4-28.9) | 41.7 (37.9-47) | 25.4 (22.5-28.8) | 42.3 (38.4-47.7) |
| Patient age; median, y (IQR) | 57.1 (41.3-65.6) | 53.4 (39-63.7) | 56.4 (40.1-64.9) | 55.9 (41.2-64.8) | 55.5 (38.5-64.1) | 54.6 (38.4-63.6) |
| Patient age, y | ||||||
| ≤55 | 729 (45.8) | 282 (53.6) | 1806 (47) | 569 (48.1) | 1310 (49.3) | 497 (50.8) |
| >55 | 862 (54.2) | 244 (46.4) | 2039 (53) | 615 (51.9) | 1349 (50.7) | 481 (49.2) |
| Disease | ||||||
| AML | 910 (57.2) | 288 (54.8) | 2164 (56.3) | 681 (57.5) | 1528 (57.5) | 543 (55.5) |
| MDS | 390 (24.5) | 112 (21.3) | 342 (24.5) | 271 (22.9) | 594 (22.3) | 222 (22.7) |
| ALL | 291 (18.3) | 126 (24.0) | 739 (19.2) | 232 (19.6) | 537 (20.2) | 213 (21.8) |
| Disease risk | ||||||
| Early-intermediate | 1052 (66.1) | 344 (65.4) | 2519 (65.5) | 776 (65.5) | 1774 (66.7) | 636 (65) |
| Advanced | 539 (33.9) | 182 (34.6) | 1326 (34.5) | 408 (34.5) | 885 (33.3) | 342 (35) |
| Conditioning | ||||||
| MAC | 919 (57.8) | 345 (65.6) | 2297 (59.7) | 743 (62.8) | 1632 (61.4) | 619 (63.3) |
| RIC/NMA | 672 (42.2) | 181 (34.4) | 1548 (40.3) | 441 (37.2) | 1027 (38.6) | 359 (36.7) |
| Graft | ||||||
| PB | 1285 (80.8) | 422 (80.2) | 3052 (79.4) | 954 (80.6) | 2101 (79.1) | 784 (80.2) |
| BM | 306 (19.2) | 104 (19.8) | 793 (20.6) | 230 (19.4) | 558 (20.9) | 194 (19.8) |
| GVHD prophylaxis | ||||||
| Tac based | 1389 (87.3) | 444 (84.4) | 3364 (87.5) | 1008 (85.1) | 2299 (86.5) | 827 (84.6) |
| CsA based | 202 (12.7) | 82 (15.6) | 481 (12.5) | 176 (14.9) | 360 (13.5) | 151 (15.4) |
| In vivo TCD | ||||||
| No | 1037 (65.2) | 328 (62.4) | 2439 (63.4) | 775 (65.5) | 1687 (63.4) | 615 (62.9) |
| Yes | 554 (34.8) | 198 (37.6) | 1406 (36.6) | 409 (34.5) | 972 (36.6) | 363 (37.1) |
| KPS | ||||||
| <90 | 641 (40.3) | 200 (38) | 1596 (41.5) | 496 (41.9) | 1081 (40.6) | 406 (41.5) |
| ≥90 | 950 (59.7) | 326 (62) | 2249 (58.5) | 688 (58.1) | 1578 (59.4) | 572 (58.5) |
| HCT-CI | ||||||
| 0-1 | 566 (35.6) | 220 (41.8) | 1401 (36.4) | 455 (38.4) | 986 (37.1) | 382 (39.1) |
| ≥2 | 1025 (64.4) | 306 (58.2) | 2444 (63.6) | 729 (61.6) | 1673 (62.9) | 596 (60.9) |
| D/R CMV | ||||||
| Pos/Pos | 417 (26.2) | 175 (33.3) | 955 (24.8) | 393 (33.2) | 676 (25.4) | 291 (29.8) |
| Pos/Neg | 154 (9.7) | 56 (10.6) | 349 (9.1) | 142 (12) | 234 (8.8) | 110 (11.2) |
| Neg/Pos | 563 (35.4) | 181 (34.4) | 1456 (37.9) | 398 (33.6) | 961 (36.1) | 349 (35.7) |
| Neg/Neg | 457 (28.7) | 114 (21.7) | 1085 (28.2) | 251 (21.2) | 788 (29.6) | 228 (23.3) |
| D/R sex | ||||||
| Others | 1389 (87.3) | 447 (85) | 3406 (88.6) | 973 (82.2) | 2347 (88.3) | 827 (84.6) |
| F-to-M | 202 (12.7) | 79 (15) | 439 (11.4) | 211 (17.8) | 312 (11.7) | 151 (15.4) |
| Race | ||||||
| White | 1484 (93.3) | 459 (87.3) | 3607 (93.8) | 1054 (89) | 2500 (94) | 888 (90.8) |
| African American | 15 (0.9) | 11 (2.1) | 45 (1.2) | 42 (3.6) | 43 (1.6) | 41 (4.2) |
| Asian | 28 (1.8) | 23 (4.4) | 76 (2) | 38 (3.2) | 58 (2.2) | 23 (2.4) |
| Other | 17 (1.1) | 12 (2.3) | 22 (0.6) | 15 (1.3) | 21 (0.8) | 7 (0.7) |
| Missing | 47 (3) | 21 (4) | 95 (2.5) | 35 (3) | 37 (1.4) | 19 (1.9) |
| Ethnicity | ||||||
| Hispanic/Latino | 116 (7.3) | 56 (10.6) | 224 (5.8) | 85 (7.2) | 125 (4.7) | 56 (5.7) |
| Not Hispanic/Latino | 1401 (88.1) | 447 (85) | 3495 (90.9) | 1052 (88.8) | 2454 (92.3) | 880 (90) |
| Nonresident United States | 44 (2.8) | 15 (2.8) | 66 (1.7) | 27 (2.3) | 39 (1.5) | 27 (2.8) |
| Missing | 30 (1.9) | 8 (1.5) | 60 (1.6) | 20 (1.7) | 41 (1.5) | 15 (1.5) |
| Year of HCT | ||||||
| ≤2014 | 663 (41.7) | 309 (58.8) | 1837 (47.8) | 691 (58.4) | 1594 (60) | 647 (66.2) |
| >2014 | 928 (58.3) | 217 (41.2) | 2008 (52.2) | 493 (41.6) | 1065 (40) | 331 (33.8) |
| Time to HCT; median, mo (IQR) | 6 (4.4-10.9) | 6.4 (4.5-12.3) | 6.1 (4.4-12.2) | 6.2 (4.6-12.7) | 6.2 (4.4-12.3) | 6.6 (4.5-12.7) |
| Follow-up among survivors; median, mo (IQR) | 39.1 (24-69.6) | 49.7 (26.3-73.5) | 47.4 (24.8-71.4) | 49.3 (30.9-73) | 58.4 (35.5-73.1) | 61.5 (36.1-95.2) |
| . | DP-matched/ younger donor . | DP-matched/ older donor . | Permissive-mismatched/ younger donor . | Permissive- mismatched/ older donor . | Nonpermissive-mismatched/ younger donor . | Nonpermissive-mismatched/ older donor . |
|---|---|---|---|---|---|---|
| n = 1591 . | n = 526 . | n = 3845 . | n = 1184 . | n = 2659 . | n = 978 . | |
| Donor age; median, y (IQR) | 25.3 (22.4-28.9) | 41.7 (38.1-47) | 25.4 (22.4-28.9) | 41.7 (37.9-47) | 25.4 (22.5-28.8) | 42.3 (38.4-47.7) |
| Patient age; median, y (IQR) | 57.1 (41.3-65.6) | 53.4 (39-63.7) | 56.4 (40.1-64.9) | 55.9 (41.2-64.8) | 55.5 (38.5-64.1) | 54.6 (38.4-63.6) |
| Patient age, y | ||||||
| ≤55 | 729 (45.8) | 282 (53.6) | 1806 (47) | 569 (48.1) | 1310 (49.3) | 497 (50.8) |
| >55 | 862 (54.2) | 244 (46.4) | 2039 (53) | 615 (51.9) | 1349 (50.7) | 481 (49.2) |
| Disease | ||||||
| AML | 910 (57.2) | 288 (54.8) | 2164 (56.3) | 681 (57.5) | 1528 (57.5) | 543 (55.5) |
| MDS | 390 (24.5) | 112 (21.3) | 342 (24.5) | 271 (22.9) | 594 (22.3) | 222 (22.7) |
| ALL | 291 (18.3) | 126 (24.0) | 739 (19.2) | 232 (19.6) | 537 (20.2) | 213 (21.8) |
| Disease risk | ||||||
| Early-intermediate | 1052 (66.1) | 344 (65.4) | 2519 (65.5) | 776 (65.5) | 1774 (66.7) | 636 (65) |
| Advanced | 539 (33.9) | 182 (34.6) | 1326 (34.5) | 408 (34.5) | 885 (33.3) | 342 (35) |
| Conditioning | ||||||
| MAC | 919 (57.8) | 345 (65.6) | 2297 (59.7) | 743 (62.8) | 1632 (61.4) | 619 (63.3) |
| RIC/NMA | 672 (42.2) | 181 (34.4) | 1548 (40.3) | 441 (37.2) | 1027 (38.6) | 359 (36.7) |
| Graft | ||||||
| PB | 1285 (80.8) | 422 (80.2) | 3052 (79.4) | 954 (80.6) | 2101 (79.1) | 784 (80.2) |
| BM | 306 (19.2) | 104 (19.8) | 793 (20.6) | 230 (19.4) | 558 (20.9) | 194 (19.8) |
| GVHD prophylaxis | ||||||
| Tac based | 1389 (87.3) | 444 (84.4) | 3364 (87.5) | 1008 (85.1) | 2299 (86.5) | 827 (84.6) |
| CsA based | 202 (12.7) | 82 (15.6) | 481 (12.5) | 176 (14.9) | 360 (13.5) | 151 (15.4) |
| In vivo TCD | ||||||
| No | 1037 (65.2) | 328 (62.4) | 2439 (63.4) | 775 (65.5) | 1687 (63.4) | 615 (62.9) |
| Yes | 554 (34.8) | 198 (37.6) | 1406 (36.6) | 409 (34.5) | 972 (36.6) | 363 (37.1) |
| KPS | ||||||
| <90 | 641 (40.3) | 200 (38) | 1596 (41.5) | 496 (41.9) | 1081 (40.6) | 406 (41.5) |
| ≥90 | 950 (59.7) | 326 (62) | 2249 (58.5) | 688 (58.1) | 1578 (59.4) | 572 (58.5) |
| HCT-CI | ||||||
| 0-1 | 566 (35.6) | 220 (41.8) | 1401 (36.4) | 455 (38.4) | 986 (37.1) | 382 (39.1) |
| ≥2 | 1025 (64.4) | 306 (58.2) | 2444 (63.6) | 729 (61.6) | 1673 (62.9) | 596 (60.9) |
| D/R CMV | ||||||
| Pos/Pos | 417 (26.2) | 175 (33.3) | 955 (24.8) | 393 (33.2) | 676 (25.4) | 291 (29.8) |
| Pos/Neg | 154 (9.7) | 56 (10.6) | 349 (9.1) | 142 (12) | 234 (8.8) | 110 (11.2) |
| Neg/Pos | 563 (35.4) | 181 (34.4) | 1456 (37.9) | 398 (33.6) | 961 (36.1) | 349 (35.7) |
| Neg/Neg | 457 (28.7) | 114 (21.7) | 1085 (28.2) | 251 (21.2) | 788 (29.6) | 228 (23.3) |
| D/R sex | ||||||
| Others | 1389 (87.3) | 447 (85) | 3406 (88.6) | 973 (82.2) | 2347 (88.3) | 827 (84.6) |
| F-to-M | 202 (12.7) | 79 (15) | 439 (11.4) | 211 (17.8) | 312 (11.7) | 151 (15.4) |
| Race | ||||||
| White | 1484 (93.3) | 459 (87.3) | 3607 (93.8) | 1054 (89) | 2500 (94) | 888 (90.8) |
| African American | 15 (0.9) | 11 (2.1) | 45 (1.2) | 42 (3.6) | 43 (1.6) | 41 (4.2) |
| Asian | 28 (1.8) | 23 (4.4) | 76 (2) | 38 (3.2) | 58 (2.2) | 23 (2.4) |
| Other | 17 (1.1) | 12 (2.3) | 22 (0.6) | 15 (1.3) | 21 (0.8) | 7 (0.7) |
| Missing | 47 (3) | 21 (4) | 95 (2.5) | 35 (3) | 37 (1.4) | 19 (1.9) |
| Ethnicity | ||||||
| Hispanic/Latino | 116 (7.3) | 56 (10.6) | 224 (5.8) | 85 (7.2) | 125 (4.7) | 56 (5.7) |
| Not Hispanic/Latino | 1401 (88.1) | 447 (85) | 3495 (90.9) | 1052 (88.8) | 2454 (92.3) | 880 (90) |
| Nonresident United States | 44 (2.8) | 15 (2.8) | 66 (1.7) | 27 (2.3) | 39 (1.5) | 27 (2.8) |
| Missing | 30 (1.9) | 8 (1.5) | 60 (1.6) | 20 (1.7) | 41 (1.5) | 15 (1.5) |
| Year of HCT | ||||||
| ≤2014 | 663 (41.7) | 309 (58.8) | 1837 (47.8) | 691 (58.4) | 1594 (60) | 647 (66.2) |
| >2014 | 928 (58.3) | 217 (41.2) | 2008 (52.2) | 493 (41.6) | 1065 (40) | 331 (33.8) |
| Time to HCT; median, mo (IQR) | 6 (4.4-10.9) | 6.4 (4.5-12.3) | 6.1 (4.4-12.2) | 6.2 (4.6-12.7) | 6.2 (4.4-12.3) | 6.6 (4.5-12.7) |
| Follow-up among survivors; median, mo (IQR) | 39.1 (24-69.6) | 49.7 (26.3-73.5) | 47.4 (24.8-71.4) | 49.3 (30.9-73) | 58.4 (35.5-73.1) | 61.5 (36.1-95.2) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CsA, cyclosporine; D/R CMV, donor/recipient cytomegalovirus status; F-to-M, female donor to male recipient; HCT-CI, HCT-specific comorbidity index; IQR, interquartile range; KPS, Karnofsky performance status; MAC, myeloablative conditioning; MDS, myelodysplastic neoplasms; Neg, negative; NMA, nonmyeloablative conditioning; PB, peripheral blood; Pos, positive; RIC, reduced intensity conditioning; Tac, tacrolimus; TCD, T-cell depletion.